Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European Union Clinical Trials Information System to advance a Phase 2b study of its prostate cancer treatment Teverelix, the company said on Monday. The planned trial will focus on patients with advanced prostate cancer and elevated cardiovascular risk who require androgen deprivation therapy (ADT), a segment the company estimates represents roughly $4 billion in annual market opportunity across major pharmaceutical markets.